Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study

被引：0

作者：

Mittelman, Moshe ^{[1
,7
]}

Platzbecker, Uwe ^{[2
]}

Grosicki, Sebastian ^{[3
]}

Lawniczek, Tomasz ^{[4
]}

Zhu, Zewen ^{[5
]}

Selleslag, Dominik ^{[6
]}

机构：

[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[2] Univ Hosp Leipzig, Med Clin & Polyclin 1, Hematol & Cellular Therapy, Leipzig, Germany

[3] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[4] Novartis Pharm AG, Basel, Switzerland

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] AZ Sint Jan Brugge Oostende AV, Dept Hematol, Brugge, Belgium

[7] Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-6423906 Tel Aviv, Israel

来源：

ACTA HAEMATOLOGICA | 2023年 / 146卷 / 05期

关键词：

Advanced myelodysplastic syndrome; Acute myeloid leukemia; Eltrombopag; Thrombocytopenia; PLACEBO; BLIND; RISK; INTERMEDIATE; ROMIPLOSTIM; MDS;

D O I：

10.1159/000531146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 x 10(9) platelets/L). Approximately 30-65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.

引用

页码：373 / 378

页数：6

共 50 条

[21] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study [J].

Deleuran, Mette ;

Thaci, Diamant ;

Beck, Lisa A. ;

de Bruin-Weller, Marjolein ;

Blauvelt, Andrew ;

Forman, Seth ;

Bissonnette, Robert ;

Reich, Kristian ;

Soong, Weily ;

Hussain, Iftikhar ;

Foley, Peter ;

Hide, Michihiro ;

Bouaziz, Jean-David ;

Gelfand, Joel M. ;

Sher, Lawrence ;

Schuttelaar, Marie L. A. ;

Wang, Chen ;

Chen, Zhen ;

Akinlade, Bolanle ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Davis, John D. ;

Rajadhyaksha, Manoj ;

Staudinger, Heribert ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Ardeleanu, Marius .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) :377-388

[22] Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2) [J].

Reich, K. ;

Wozel, G. ;

Zheng, H. ;

van Hoogstraten, H. J. F. ;

Flint, L. ;

Barker, J. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (06) :1325-1334

[23] Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results [J].

Fleischer, David M. ;

Shreffler, Wayne G. ;

Campbell, Dianne E. ;

Green, Todd D. ;

Anvari, Sara ;

Assa'ad, Amal ;

Begin, Philippe ;

Beyer, Kirsten ;

Bird, J. Andrew ;

Brown-Whitehorn, Terri ;

Byrne, Aideen ;

Chan, Edmond S. ;

Cheema, Amarjit ;

Chinthrajah, Sharon ;

Chong, Hey Jin ;

Davis, Carla M. ;

Ford, Lara S. ;

Gagnon, Remi ;

Greenhawt, Matthew ;

Hourihane, Jonathan O'B ;

Jones, Stacie M. ;

Kim, Edwin H. ;

Lange, Lars ;

Lanser, Bruce J. ;

Leonard, Stephanie ;

Mahler, Vera ;

Maronna, Andreas ;

Nowak-Wegrzyn, Anna ;

Oriel, Roxanne C. ;

O'Sullivan, Michael ;

Petroni, Daniel ;

Pongracic, Jacqueline A. ;

Prescott, Susan L. ;

Schneider, Lynda C. ;

Smith, Peter ;

Staab, Doris ;

Sussman, Gordon ;

Wood, Robert ;

Yang, William H. ;

Lambert, Romain ;

Peillon, Aurelie ;

Bois, Timothee ;

Sampson, Hugh A. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (04) :863-874

[24] Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study [J].

Mita, Tomoya ;

Katakami, Naoto ;

Yoshii, Hidenori ;

Onuma, Tomio ;

Kaneto, Hideaki ;

Osonoi, Takeshi ;

Shiraiwa, Toshihiko ;

Yasuda, Tetsuyuki ;

Umayahara, Yutaka ;

Yamamoto, Tsunehiko ;

Yokoyama, Hiroki ;

Kuribayashi, Nobuichi ;

Jinnouchi, Hideaki ;

Gosho, Masahiko ;

Shimomura, Iichiro ;

Watada, Hirotaka .

SCIENTIFIC REPORTS, 2023, 13 (01)

[25] Long-term safety and efficacy of armodafinil in bipolar depression: A 6-month open-label extension study [J].

Ketter, Terence A. ;

Amchin, Jess ;

Frye, Mark A. ;

Gross, Nicholas .

JOURNAL OF AFFECTIVE DISORDERS, 2016, 197 :51-57

[26] Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis [J].

Zhu, Sheng ;

Liu, Gang ;

Liu, Jing ;

Chen, Qiuying ;

Wang, Zhiqiang .

FRONTIERS IN ONCOLOGY, 2020, 10

[27] Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes [J].

Duncan, Christine N. ;

Majhail, Navneet S. ;

Brazauskas, Ruta ;

Wang, Zhiwei ;

Cahn, Jean-Yves ;

Frangoul, Haydar A. ;

Hayashi, Robert J. ;

Hsu, Jack W. ;

Kamble, Rammurti T. ;

Kasow, Kimberly A. ;

Khera, Nandita ;

Lazarus, Hillard M. ;

Loren, Alison W. ;

Marks, David I. ;

Maziarz, Richard T. ;

Mehta, Paulette ;

Myers, Kasiani C. ;

Norkin, Maxim ;

Pidala, Joseph A. ;

Porter, David L. ;

Reddy, Vijay ;

Saber, Wael ;

Savani, Bipin N. ;

Schouten, Harry C. ;

Steinberg, Amir ;

Wall, Donna A. ;

Warwick, Anne B. ;

Wood, William A. ;

Yu, Lolie C. ;

Jacobsohn, David A. ;

Sorror, Mohamed L. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (01) :151-158

[28] Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes [J].

Garcia-Manero, Guillermo ;

Pemmaraju, Naveen ;

Alvarado, Yesid ;

Naqvi, Kiran ;

Ravandi, Farhad ;

Jabbour, Elias ;

De Lumpa, Ricardo ;

Kantarjian, Hagop ;

Advani, Anjali ;

Mukherjee, Sudipto ;

Gerds, Aaron ;

Carraway, Hetty E. ;

Nazha, Aziz ;

Iwamura, Hiroyuki ;

Murase, Motohiko ;

Bavisotto, Linda ;

Kurman, Michael ;

Maier, Gary ;

Johansen, Mary ;

Sekeres, Mikkael A. .

LEUKEMIA & LYMPHOMA, 2020, 61 (08) :1943-1953

[29] Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study [J].

Trauner, Michael ;

Nevens, Frederik ;

Shiffman, Mitchell L. ;

Drenth, Joost P. H. ;

Bowlus, Christopher L. ;

Vargas, Victor ;

Andreone, Pietro ;

Hirschfield, Gideon M. ;

Pencek, Richard ;

Malecha, Elizabeth Smoot ;

MacConell, Leigh ;

Shapiro, David .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (06) :445-453

[30] LONG-TERM RESULTS OF TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKEMIA ACCORDING TO THE PROTOCOL OF THE RUSSIAN MULTICENTER RANDOMIZED TRIAL OF AML-10 [J].

Savchenko, V. G. ;

Parovichnikova, E. N. ;

Troitskaya, V. V. ;

Sokolov, A. N. ;

Klyasova, G. A. ;

Kuzmina, L. A. ;

Drokov, M. Yu ;

Obukhova, T. N. ;

Kulikov, S. M. .

GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2016, 61 (02) :60-65

← 1 2 3 4 5 →